Navigation Links
DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
Date:6/15/2010

cemic control.(vi,vii)

About BYETTA® (exenatide) injection

BYETTA is the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight-loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. See important safety information below. Additional information about BYETTA is available at www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection

Based on post-marketing data, BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood s
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
(Date:12/19/2014)... CITY, Calif. , Dec. 19, 2014 Bina ... , USA) announced today that they have been acquired ... 1,2 is a privately held company that provides ... of next generation sequencing (NGS) data for the academic ... the Roche Sequencing Unit, and will continue to focus ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ) ... Innovations in Smart Fabrics (Technical Insights)" report ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service titled ... assessment on technological advancements and market for Smart ... 1. The Smart Fabrics market is expected to ...
(Date:12/19/2014)... Today, TiFiber, Inc. ... facility and future company headquarters in Fort Smith, ... materials that safely and effectively control dangerous microorganisms. ... its historic, strong support for manufacturing, but also ... edge, technology-based companies such as TiFiber. , ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Innovations in Smart Fabrics (Technical Insights) 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... Rapid Production, Increased Bioavailability, MOUNTAIN VIEW, Calif., ... are either incurable or difficult to treat allures ... prized, due to their,therapeutic potential, stem cell therapies ... Stem cell research progresses at a fast pace; ...
... Inc. (Nasdaq: CEPH ) and Eurand NV ... Paragraph IV Certification Notice Letter on October 20, ... to the U.S.,Food and Drug Administration (FDA) by ... a generic version of the 15 mg and,30 ...
... 71% of Evaluable Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... Second Stage-, TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... cancer and serious viral,infections, today announced that updated preliminary data from ...
Cached Biology Technology:Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 2Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 4Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... biologist is part of a team of researchers that has unlocked ... microscopic creatures. That first peek inside, recently published in the ... of the top three scientific journals in the world may ... the way it functions. "The organisms that live in soil ...
... Until today, Alfred Russell Wallace,s century old map from ... global biodiversity. Thanks to advances in modern technology and ... of Copenhagen have now produced a next generation map ... in Science Express today, the new map ...
... The Burgess Shale provides us with a rare glimpse into ... bones, teeth and shells but one of the most ... soft body structures like gills and eyes delicately preserved between the ... Shale has been giving us a unique perspective on what life ...
Cached Biology News:Biologists unlock 'black box' to underground world 2Wallace's century-old map of natural world updated 2